Ngenla (somatrogon), from Pfizer, and Boehringer Ingelheim’s Ofev (nintedanib) have become the first two drugs to be recommended for use on the National Health Service in England after being evaluated under the new proportionate approach that NICE introduced to speed up its health technology appraisals (HTAs) of simpler, low-risk treatments.
Ngenla, a weekly injection for treating growth failure in children, was evaluated by NICE 25% faster than "the usual cost...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?